XBiotech Inc. (XBIT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
XBiotech Inc. (XBIT) trades at $2.27 with AI Score 53/100 (Grade B). XBiotech Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing True Human monoclonal antibodies. Market cap: $69.4M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 9, 2026Analyst Coverage for XBIT: XBIT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XBIT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
XBIT: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
XBiotech Inc. (XBIT) Healthcare & Pipeline Overview
XBiotech Inc., a biopharmaceutical company, develops True Human monoclonal antibodies for inflammatory and infectious diseases. Their focus on interleukin-1 alpha therapies positions them in the competitive biotechnology sector, targeting conditions like cancer, stroke, and arthritis. The company operates from its headquarters in Austin, Texas.
What Is the Investment Thesis for XBIT?
XBiotech Inc. presents a focused investment opportunity within the biotechnology sector, centered on its True Human monoclonal antibody platform. The company's pipeline, targeting inflammatory and infectious diseases, holds potential for significant growth, particularly through its interleukin-1 alpha (IL-1α) therapies. These therapies aim to address conditions like cancer, stroke, and arthritis, where IL-1α plays a critical role. A key value driver is the successful development and commercialization of these therapies, contingent on positive clinical trial outcomes and regulatory approvals. The company's market capitalization is approximately $0.07 billion, reflecting both the potential and the risks associated with its developmental stage. Upcoming clinical trial results will likely serve as major catalysts. However, the company faces risks related to clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
Based on FMP financials and quantitative analysis
XBIT Key Highlights
- XBiotech Inc. focuses on True Human monoclonal antibodies for treating various diseases.
- The company's pipeline targets both inflammatory and infectious diseases.
- XBiotech is developing interleukin-1 alpha therapies for conditions like cancer, stroke, heart attack, and arthritis.
- The company is also developing True Human COVID-19 therapy for treating the COVID-19 mutant virus.
- XBiotech Inc. was incorporated in 2005 and is headquartered in Austin, Texas.
Who Are XBIT's Competitors?
XBIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $369.39 | +0.91% | $200B | 84 |
| GILD Gilead Sciences, Inc. | $129.80 | -0.41% | $161B | 94 |
| VRTX Vertex Pharmaceuticals Incorporated | $473.09 | +0.11% | $121B | 99 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.16 | +3.48% | $170M | 75 |
| CGEN Compugen Ltd. | $2.34 | -3.31% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.19 | -6.04% | $254M | 69 |
| BLRX BioLineRx Ltd. | $2.86 | +0.41% | $12.4M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XBIT's Key Strengths?
- Proprietary True Human monoclonal antibody platform
- Focus on interleukin-1 alpha (IL-1α) therapies
- Potential for therapies targeting unmet medical needs
- Experienced management team
What Are XBIT's Weaknesses?
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Small number of employees
- Limited commercialization experience
What Could Drive XBIT Stock Higher?
- Clinical trial results for interleukin-1 alpha (IL-1α) therapies in cancer treatment.
- Regulatory submissions for True Human COVID-19 therapy.
- Expansion of strategic partnerships and collaborations.
- Advancements in the True Human antibody platform.
What Are the Key Risks for XBIT?
- Negative return on equity (-26.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for key therapeutic candidates.
- Regulatory delays or rejections for new therapies.
- Competition from established pharmaceutical companies.
- Dependence on limited financial resources.
- Patent expiration and intellectual property challenges.
What Are the Growth Opportunities for XBIT?
- Development of Interleukin-1 Alpha (IL-1α) Therapies: XBiotech's focus on IL-1α therapies presents a significant growth opportunity. IL-1α is a key mediator of inflammation and tissue breakdown, implicated in various diseases such as cancer, stroke, heart attack, and arthritis. Successful development and commercialization of these therapies could address a substantial market need, potentially generating significant revenue.
- Expansion of True Human Antibody Platform: XBiotech's True Human antibody platform offers a versatile foundation for developing therapies against a wide range of diseases. By expanding this platform and identifying new antibody targets, XBiotech can create a pipeline of novel therapeutic candidates. This approach allows for diversification of the company's product portfolio and reduces reliance on a single therapeutic area. The market for antibody-based therapies is projected to continue growing, driven by their specificity and efficacy.
- Strategic Partnerships and Collaborations: XBiotech can pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships can provide access to additional funding, expertise, and resources, enhancing XBiotech's capabilities and expanding its market reach. Collaborations can also facilitate the entry into new therapeutic areas and geographic markets, contributing to long-term growth.
- Advancement of COVID-19 Therapy: The development of a True Human COVID-19 therapy targeting mutant viruses presents a timely growth opportunity. As the COVID-19 pandemic continues to evolve, new variants emerge, necessitating the development of effective treatments. XBiotech's therapy has the potential to address this ongoing need, providing a valuable tool in the fight against the virus. The market for COVID-19 therapies remains significant, offering a potential revenue stream for XBiotech.
- Geographic Expansion: XBiotech can expand its geographic presence by entering new markets and establishing distribution networks. This expansion can increase the company's revenue base and reduce its dependence on a single geographic region. Emerging markets, in particular, offer significant growth potential due to their increasing healthcare spending and unmet medical needs. Successful geographic expansion requires careful planning and execution, including regulatory approvals and market access strategies.
What Opportunities Does XBIT Have?
- Strategic partnerships and collaborations
- Expansion into new therapeutic areas
- Geographic expansion
- Advancement of COVID-19 therapy
What Threats Does XBIT Face?
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expiration
What Are XBIT's Competitive Advantages?
- Proprietary True Human monoclonal antibody platform.
- Pipeline of product candidates targeting unmet medical needs.
- Expertise in developing therapies for inflammatory and infectious diseases.
What Does XBIT Do?
XBiotech Inc., established in 2005 and headquartered in Austin, Texas, is a biopharmaceutical company dedicated to discovering, developing, and commercializing True Human monoclonal antibodies. These antibodies are designed for treating a range of diseases, with a primary focus on inflammatory and infectious conditions. The company's core strategy revolves around creating a pipeline of product candidates that address unmet medical needs in various therapeutic areas. XBiotech's lead programs center on interleukin-1 alpha (IL-1α) therapies. IL-1α is a potent mediator of inflammation and tissue breakdown, playing a significant role in diseases such as cancer, stroke, heart attack, and arthritis. By targeting IL-1α, XBiotech aims to develop treatments that can reduce inflammation, prevent tissue damage, and improve patient outcomes. Their pipeline also includes True Human COVID-19 therapy, targeting the COVID-19 mutant virus. Since its inception, XBiotech has focused on leveraging its True Human antibody platform to create therapies that are both effective and well-tolerated. The company's approach involves identifying and isolating naturally occurring human antibodies that have the potential to neutralize disease-causing targets. These antibodies are then developed into therapeutic candidates for clinical testing and potential commercialization. XBiotech's commitment to innovation and its focus on True Human antibodies differentiate it in the competitive biotechnology landscape.
What Products and Services Does XBIT Offer?
- Discovers True Human monoclonal antibodies.
- Develops True Human monoclonal antibodies for treating various diseases.
- Commercializes True Human monoclonal antibodies.
- Focuses on therapies for inflammatory diseases.
- Develops therapies for infectious diseases.
- Targets interleukin-1 alpha to treat medical conditions.
- Develops True Human COVID-19 therapy for treating the COVID-19 mutant virus.
How Does XBIT Make Money?
- Discovers and develops True Human monoclonal antibodies.
- Out-licenses or sells developed therapies to pharmaceutical companies.
- Generates revenue through research grants and collaborations.
What Industry Does XBIT Operate In?
XBiotech Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for monoclonal antibody therapies is substantial, driven by the increasing prevalence of chronic diseases and advancements in biotechnology. Companies like XBiotech face the challenge of navigating complex regulatory pathways, securing funding for research and development, and competing with larger, more established pharmaceutical companies. The biotechnology industry is experiencing growth, fueled by technological advancements and increasing investment in healthcare.
Who Are XBIT's Key Customers?
- Pharmaceutical companies seeking novel therapies.
- Patients suffering from inflammatory diseases.
- Patients suffering from infectious diseases.
F-Score 1/9Financial Health
XBiotech Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.97 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE -26%Key Financial Metrics
Return on equity for XBiotech Inc. stands at -26.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -28.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -60.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 39.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -57.5%, the inverse of the P/E and a quick read on earnings relative to price.
XBIT Valuation & Market Position
With a $69.4M market cap, XBiotech Inc. sits in the micro-cap segment of the market. Relative to its peer group, XBIT's quantitative score of 53/100 is below the peer average of 85/100.
XBIT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, which can positively influence market sentiment.
- Community sentiment has shifted positively, with many investors expressing optimism about upcoming product developments.
- The company's focus on innovative therapies aligns with growing demand for biotech solutions, attracting attention from potential investors.
- Recent partnerships and collaborations have strengthened XBiotech's market position, enhancing its credibility among stakeholders.
Bear Case
- Concerns about regulatory approvals for their therapies have created uncertainty among investors, dampening enthusiasm.
- Social media sentiment has seen a rise in skepticism, with some community members questioning the company's long-term viability.
- Increased competition in the biotech space could pose a threat to XBiotech's market share and growth potential.
- Recent earnings calls indicated challenges in scaling operations, leading to doubts about the company's ability to meet future demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
XBIT Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Aug 31, 2022
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Apr 25, 2022
XBIT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XBIT.
Price Targets
Wall Street price target analysis for XBIT.
XBIT MoonshotScore
What does this score mean?
The MoonshotScore rates XBIT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Sushma Shivaswamy
CEO
Sushma Shivaswamy serves as the CEO of XBiotech Inc., leading the company's efforts in discovering, developing, and commercializing True Human monoclonal antibodies. Her background includes extensive experience in the biopharmaceutical industry, with a focus on strategic planning, product development, and commercialization. She has a proven track record of driving innovation and building successful teams. Her expertise spans various therapeutic areas, including inflammation and infectious diseases. Sushma is responsible for overseeing all aspects of XBiotech's operations, from research and development to manufacturing and commercialization.
Track Record: Under Sushma Shivaswamy's leadership, XBiotech Inc. has focused on advancing its pipeline of True Human monoclonal antibody therapies. She has overseen the development of interleukin-1 alpha (IL-1α) therapies targeting conditions like cancer, stroke, and arthritis. Her strategic decisions have guided the company's research and development efforts, positioning XBiotech as an innovator in the biotechnology sector. She manages a team of 92 employees.
What Investors Ask About XBiotech Inc. (XBIT) — Healthcare
What does the AI Score mean for XBIT?
XBIT holds an AI Score of 53/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. XBiotech Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing True Human monoclonal antibodies. Their pipeline targets inflammatory and infectious diseases …
What does XBiotech Inc. do?
XBiotech Inc. is a biopharmaceutical company that discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. Its lead programs center on interleukin-1 alpha (IL-1α) therapies, which aim to address conditions like cancer, stroke, heart attack, and arthritis.
What do analysts say about XBIT stock?
As of May 9, 2026, analyst coverage of XBIT stock is limited, reflecting the company's small market capitalization and developmental stage. Key valuation metrics are influenced by the potential success of its pipeline, particularly the interleukin-1 alpha (IL-1α) therapies and the True Human COVID-19 therapy. Growth considerations center on the successful completion of clinical trials and regulatory approvals.
What are the main risks for XBIT?
XBiotech Inc. faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as the success of its pipeline depends on positive outcomes. Regulatory hurdles, including potential delays or rejections, can also impact the company's ability to bring its therapies to market.
What are the key factors to evaluate for XBIT?
XBiotech Inc. (XBIT) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does XBIT data refresh on this page?
XBIT's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven XBIT's recent stock price performance?
XBiotech Inc. (XBIT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary True Human monoclonal antibody platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XBIT overvalued or undervalued right now?
XBiotech Inc. (XBIT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XBIT before investing?
Before investing in XBiotech Inc. (XBIT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of May 9, 2026.
- Financial metrics are subject to change based on market conditions and company performance.
- Clinical trial outcomes are inherently uncertain.